Octreotide in the treatment of lymphorrhea after axillary node dissection: a prospective randomized controlled trial.

Carcoforo P, Soliani G, Maestroni U, Donini A, Inderbitzin D, Hui TT, Lefor A, Avital I, Navarra G

Journal of the American College of Surgeons1 Mar 2003Cited by 50 (Europe PMC)

PMID12648685DOI10.1016/s1072-7515(02)01757-xPepBankPUB-12648685

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
After axillary dissection for breast cancer, daily lymphorrhea was 65.4 +/- 21.1 cc with octreotide versus 94.6 +/- 19 without treatment (p < 0.0001).
In plain wordsAfter breast cancer node surgery, octreotide reduced daily lymph leakage compared with no treatment.
Peptide
Octreotide
Outcome
DecreaseDaily lymphorrhea volume
Study
n = 261
Comparator
No treatment
Outcome group
Wound healing · Skin and wound
Studied dose
0.1 mg three times a day · subcutaneous · 5 daysAs given in this study (human).
Measurements
Mean daily lymphorrhea
65.4 cc/day
octreotide group; reported +/- 21.1
Mean daily lymphorrhea
94.6 cc/day
control group; reported +/- 19
Source sentences
Summary
In comparison, the mean quantity of lymphorrhea in the treatment group was 65.4 +/- 21.1 cc (p < 0.0001) per day and the average duration was 7.1 +/- 2.9 days (p < 0.0001).
4 context sentences(design, population, supporting numbers)
Summary · context
In the control group, the mean quantity (+/- standard deviation) of lymphorrhea was 94.6 +/- 19 cc per day and the average duration was 16.7 +/- 3.0 days.
Summary · context
Two hundred sixty-one consecutive patients with various stages of breast cancer who underwent axillary lymph node dissection were randomized and followed for 7 years.
Summary · context
The treatment group received 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day, while the control group received no treatment.
Summary · context
Of the 261 patients undergoing axillary node dissection, 136 were assigned to the control group and 125 composed the treatment group.
Report a problemFND-1264868501
02HumanRandomized controlled trialEfficacy outcome
After axillary dissection for breast cancer, lymphorrhea lasted 7.1 +/- 2.9 days with octreotide versus 16.7 +/- 3.0 without treatment (p < 0.0001).
In plain wordsAfter breast cancer node surgery, octreotide shortened lymph leakage compared with no treatment.
Peptide
Octreotide
Outcome
DecreaseLymphorrhea duration
Study
n = 261
Comparator
No treatment
Outcome group
Wound healing · Skin and wound
Studied dose
0.1 mg three times a day · subcutaneous · 5 daysAs given in this study (human).
Measurements
Mean lymphorrhea duration
7.1 days
octreotide group; reported +/- 2.9
Mean lymphorrhea duration
16.7 days
control group; reported +/- 3.0
Source sentences
Summary
In comparison, the mean quantity of lymphorrhea in the treatment group was 65.4 +/- 21.1 cc (p < 0.0001) per day and the average duration was 7.1 +/- 2.9 days (p < 0.0001).
4 context sentences(design, population, supporting numbers)
Summary · context
In the control group, the mean quantity (+/- standard deviation) of lymphorrhea was 94.6 +/- 19 cc per day and the average duration was 16.7 +/- 3.0 days.
Summary · context
Two hundred sixty-one consecutive patients with various stages of breast cancer who underwent axillary lymph node dissection were randomized and followed for 7 years.
Summary · context
The treatment group received 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day, while the control group received no treatment.
Summary · context
Of the 261 patients undergoing axillary node dissection, 136 were assigned to the control group and 125 composed the treatment group.
Report a problemFND-1264868502
03HumanRandomized controlled trialSafety outcome
After axillary dissection, infectious complication counts showed no important difference between octreotide and no treatment.
In plain wordsAfter node surgery, infection counts showed no important difference between octreotide and no treatment.
Peptide
Octreotide
Outcome
No significant changeInfectious complications
Study
n = 261
Comparator
No treatment
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
0.1 mg three times a day · subcutaneous · 5 daysAs given in this study (human).
Source sentences
Summary
We did not find an important difference in the number of infectious complication or hematomas formation between the study groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Two hundred sixty-one consecutive patients with various stages of breast cancer who underwent axillary lymph node dissection were randomized and followed for 7 years.
Summary · context
The treatment group received 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day, while the control group received no treatment.
Summary · context
Of the 261 patients undergoing axillary node dissection, 136 were assigned to the control group and 125 composed the treatment group.
Report a problemFND-1264868503
04HumanRandomized controlled trialSafety outcome
After axillary dissection, hematoma formation showed no important difference between octreotide and no treatment.
In plain wordsAfter node surgery, blood collection under the skin showed no important difference between octreotide and no treatment.
Peptide
Octreotide
Outcome
No significant changeHematoma formation
Study
n = 261
Comparator
No treatment
Outcome group
Adverse events · Skin and wound
Studied dose
0.1 mg three times a day · subcutaneous · 5 daysAs given in this study (human).
Source sentences
Summary
We did not find an important difference in the number of infectious complication or hematomas formation between the study groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Two hundred sixty-one consecutive patients with various stages of breast cancer who underwent axillary lymph node dissection were randomized and followed for 7 years.
Summary · context
The treatment group received 0.1 mg octreotide subcutaneously three times a day for 5 days, starting on the first postoperative day, while the control group received no treatment.
Summary · context
Of the 261 patients undergoing axillary node dissection, 136 were assigned to the control group and 125 composed the treatment group.
Report a problemFND-1264868504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT05682209

The Effect of Octreotide on Wound Drainage After Mastectomy

Ikechukwu Bartholomew Ulasin = 4118 Dec 2020 to 2 Dec 2021

Seroma Following Procedure

Trial page ClinicalTrials.govUpdated 18 Jan 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.